Tarsus Pharmaceuticals Financial Statements
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tarsus Pharmaceuticals revenue and earnings
In fiscal 2025, Tarsus Pharmaceuticals generated $451.4 million in revenue, up 146.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Tarsus Pharmaceuticals reported a net loss of $66.4 million, compared with a loss of $115.6 million a year earlier. Operating margin was -15.7%.
Diluted earnings per share came in at -$1.59.
Summary generated from market data by MetaCap's automated system. Methodology
Tarsus Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M | 0 | — | — |
| Revenue growth (YoY) | +146.71% | +948.62% | -32.42% | -54.73% | — | — | — | — |
| Operating Expenses | — | — | 160.60M | 88.53M | 69.18M | 27.00M | 4.30M | — |
| Research & Development | 64.32M | 53.39M | 50.31M | 42.62M | 41.71M | 18.83M | 3.16M | — |
| Selling, General & Admin | 427.32M | 237.31M | 108.70M | 44.95M | — | — | — | — |
| Operating Income | -70.97M | -120.57M | -143.16M | -62.71M | -12.16M | -27.00M | -4.30M | — |
| Interest Expense | 8.94M | 7.85M | 3.35M | 2.20M | 0 | — | — | — |
| Other Income (Expense) | 6.61M | 5.01M | 7.26M | 617.00K | -1.61M | 188.00K | -371.00K | — |
| Pretax Income | -64.36M | -115.55M | -135.89M | -62.09M | -13.77M | -26.81M | — | — |
| Income Tax | 2.06M | 0 | 0 | -4.00K | 55.00K | 1.00K | 1.00K | — |
| Net Income | -66.42M | -115.55M | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 | -1.98 | — |
| EPS (Diluted) | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 | -1.98 | — |
| Shares Outstanding (Basic) | 41.78M | 37.60M | 29.38M | 24.62M | 20.55M | 6.21M | 2.36M | — |
| Shares Outstanding (Diluted) | 41.78M | 37.60M | 29.38M | 24.62M | 20.55M | 6.21M | 2.36M | — |
| EBITDA | -70.11M | -119.88M | -142.41M | -62.39M | -11.86M | -26.90M | -4.26M | — |
| Operating Margin | -15.72% | -65.90% | -820.53% | -242.92% | -21.32% | — | — | — |
| Net Margin | -14.72% | -63.16% | -778.89% | -240.51% | -24.25% | — | — | — |
This table shows 8 annual periods of Tarsus Pharmaceuticals's income statement, from FY 2025 back to FY 2018, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow TARS's reporting calendar. What is a income statement?